LONG READControl of empty, full and partially filled capsids BioPhorum establishing an industry position on this critical quality attributePosition A consensus of BioPhorum member companies reject a proposed blanket minimum specification for percentage empty AAV capsids. Presently, it is premature and impractical to set a minimal specification of <30% empty capsids to apply to all AAV-based gene therapies in development.BioPhorum calls upon...
Deliverables Report
Viewing related articles
read more
How industry is reacting to the Covid-19 pandemic
Jan 2021 | Cell & Gene Therapy, COVID 19, Covid-19, Deliverables Report, Development Group, Drug Substance, Fill Finish, Information Technology, Long Read, MediPhorum, Publication, Regulatory, Supply Partner, Technology Strategy
LONG READHow industry is reacting to the Covid-19 pandemicKeeping in touch with peers and colleagues has never been more important. Following the postponement of meetings such as the annual Executive BioPhorum meeting, coupled with the heightened need for communication between industry leaders, BioPhorum established the Senior BioPhorum Connect – a group for senior leaders to share ideas, discuss problems and find solutions to counter the...